Deutsche Märkte öffnen in 8 Stunden 47 Minuten

InMed Pharmaceuticals Inc. (IN.TO)

Toronto - Toronto Echtzeitpreis. Währung in CAD
Zur Watchlist hinzufügen
4,1900-0,0700 (-1,64%)
Börsenschluss: 04:00PM EDT

InMed Pharmaceuticals Inc.

815 West Hastings Street
Suite 310
Vancouver, BC V6C 1B4
Canada

https://www.inmedpharma.com

Sektor(en)
Branche
Vollzeitmitarbeiter12

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Eric A. AdamsPres, CEO & Director488,44kN/A1964
Ms. Alexandra Diane-Janet ManciniSr. VP of Clinical & Regulatory Affairs337,13kN/A1953
Mr. Bruce S. Colwill C.A., CPA, CAAdvisor397,54kN/A1965
Dr. Sazzad Hossain M.Sc., Ph.D.Co-FounderN/AN/A1958
Ms. Brenda Edwards C.M.A., CPAInterim Chief Financial OfficerN/AN/AN/A
Colin ClancySr. Director of Investor RelationsN/AN/AN/A
Mr. Jerry P. GriffinVP of Sales & MarketingN/AN/AN/A
Dr. Eric Chih-Hsien HsuSr. VP of Preclinical R&DN/AN/A1970
Mr. Michael Woudenberg P.Eng.Sr. VP of Chemistry, Manufacturing & ControlsN/AN/A1968
Dr. Shane A. Johnson Ph.D.Sr. VP & GM of BayMedicaN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CAD.

Beschreibung

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Corporate Governance

InMed Pharmaceuticals Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.